Ten abstracts featuring Boehringer Ingelheim's investigational hepatitis C virus protease inhibitor, faldaprevir*and polymerase inhibitor, deleobuvir* will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases 2013, 1-5 November, Washington.1 Faldaprevir* is a second generation protease inhibitor and is ... (more)
http://eon.businesswire.com/news/eon/20131001006488/en/Boehringer-Ingelheim-announce-pivotal-Phase-III-hepatitis
http://eon.businesswire.com/news/eon/20131001006488/en/Boehringer-Ingelheim-announce-pivotal-Phase-III-hepatitis
No comments:
Post a Comment